Amarin Corp Plc (AMRN)

[Pharmacydude]

Raf
I take most of these studies by Preston Mason to be focused on the potential in COVID although he sights their potential benefits in CVD. The combination of use with colchicine was PROBABLY initiated because of the suspected benefits of colchicine in Covid. Two major trials (Montreal and Argentina) have both shown modest benefits with colchicine but they have a shared anti-inflammatory effect.
The numerous studies testing the benefits of EPA on IL-6 (a primary driver of inflammation and a key driver of the cytokine storm) challenged tissues is akin to testing how EPA would protect against Covid. These are very encouraging! IL-6 is also a key player in the inflammatory response to plaque and thus relevant to CVD as well but IL-6 is the hottest topic in Covid research at the moment.
All of Mason’s study results are supportive of the theoretical benefits of EPA in Covid (as well as CVD).